SVB Leerink analyst Andrew Berens maintains Blueprint Medicines (NASDAQ:BPMC) with a Market Perform and lowers the price target from $60 to $56.
Sky’s the Limit: Morgan Stanley Analyst Sees Huge Upside for Meta Platforms
Morgan Stanley analyst Brian Nowak reiterated an Overweight rating on Meta Platforms, Inc (NASDAQ: META) with a